BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 35283317)

  • 21. Hepatitis B virus reactivation in patients undergoing immune checkpoint inhibition: systematic review with meta-analysis.
    Ding ZN; Meng GX; Xue JS; Yan LJ; Liu H; Yan YC; Chen ZQ; Hong JG; Wang DX; Dong ZR; Li T
    J Cancer Res Clin Oncol; 2023 May; 149(5):1993-2008. PubMed ID: 35767193
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hepatitis B-related outcomes following direct-acting antiviral therapy in Taiwanese patients with chronic HBV/HCV co-infection.
    Yeh ML; Huang CF; Huang CI; Holmes JA; Hsieh MH; Tsai YS; Liang PC; Tsai PC; Hsieh MY; Lin ZY; Chen SC; Huang JF; Dai CY; Chuang WL; Chung RT; Yu ML
    J Hepatol; 2020 Jul; 73(1):62-71. PubMed ID: 32061869
    [TBL] [Abstract][Full Text] [Related]  

  • 23. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Agents targeting lymphoid or myeloid cells surface antigens [II]: CD22, CD30, CD33, CD38, CD40, SLAMF-7 and CCR4).
    Drgona L; Gudiol C; Lanini S; Salzberger B; Ippolito G; Mikulska M
    Clin Microbiol Infect; 2018 Jun; 24 Suppl 2():S83-S94. PubMed ID: 29572070
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacotherapeutic strategies for hepatitis B and hepatitis C coinfection.
    Jacob R; Danta M
    Expert Opin Pharmacother; 2022 Mar; 23(4):465-472. PubMed ID: 34937470
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Reactivation rates of hepatitis B or C or HIV in patients with psoriasis using biological therapies: a systematic review and meta-analysis.
    Li L; Jiang X; Fu L; Zhang L; Feng Y
    Clin Exp Med; 2023 Jul; 23(3):701-715. PubMed ID: 35499793
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hepatitis B virus reactivation after treatment for hepatitis C in hemodialysis patients with HBV/HCV coinfection.
    Wahle RC; Perez RM; Pereira PF; Oliveira EM; Emori CT; Uehara SN; Silva IS; Silva AE; Ferraz ML
    Braz J Infect Dis; 2015; 19(5):533-7. PubMed ID: 25997784
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Advances in the treatment of hepatitis B virus/hepatitis C virus coinfection.
    Sagnelli E; Pisaturo M; Martini S; Sagnelli C; Filippini P; Coppola N
    Expert Opin Pharmacother; 2014 Jul; 15(10):1337-49. PubMed ID: 24773464
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Expressions of inhibitory checkpoint molecules in acute and chronic HBV and HCV infections: Implications for therapeutic monitoring and personalized therapy.
    Hakim MS; Rahmadika N; Jariah ROA
    Rev Med Virol; 2020 Mar; 30(2):e2094. PubMed ID: 31825155
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A case of acute hepatitis B in a chronic hepatitis C patient after daclatasvir and asunaprevir combination therapy: hepatitis B virus reactivation or acute self-limited hepatitis?
    Hayashi K; Ishigami M; Ishizu Y; Kuzuya T; Honda T; Nishimura D; Goto H; Hirooka Y
    Clin J Gastroenterol; 2016 Aug; 9(4):252-6. PubMed ID: 27329484
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Risk for hepatitis B and C virus reactivation in patients with psoriasis on biologic therapies: A retrospective cohort study and systematic review of the literature.
    Snast I; Atzmony L; Braun M; Hodak E; Pavlovsky L
    J Am Acad Dermatol; 2017 Jul; 77(1):88-97.e5. PubMed ID: 28495497
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hepatitis C virus reactivation in cancer patients in the era of targeted therapies.
    Yazici O; Sendur MA; Aksoy S
    World J Gastroenterol; 2014 Jun; 20(22):6716-24. PubMed ID: 24944464
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Does hepatitis C virus affect the reactivation of hepatitis B virus following renal transplantation?
    Yen TH; Huang CC; Lin HH; Huang JY; Tian YC; Yang CW; Wu MS; Fang JT; Yu CC; Chiang YJ; Chu SH
    Nephrol Dial Transplant; 2006 Apr; 21(4):1046-52. PubMed ID: 16390851
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immune checkpoint inhibitor use and the incidence of hepatitis B virus reactivation or immune-related hepatitis in non-small cell lung cancer patients with chronic hepatitis B.
    Hong J; Lee J; Park S; Jung HA; Sun JM; Lee SH; Ahn JS; Sinn DH; Ahn MJ
    Cancer; 2024 May; 130(9):1693-1701. PubMed ID: 38165808
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Reactivation of hepatitis B in patients of chronic hepatitis C with hepatitis B virus infection treated with direct acting antivirals.
    Yeh ML; Huang CF; Hsieh MH; Ko YM; Chen KY; Liu TW; Lin YH; Liang PC; Hsieh MY; Lin ZY; Chen SC; Huang CI; Huang JF; Kuo PL; Dai CY; Yu ML; Chuang WL
    J Gastroenterol Hepatol; 2017 Oct; 32(10):1754-1762. PubMed ID: 28230928
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Direct-acting antivirals and hepatitis B virus (HBV) reactivation in co-infected HBV/HCV kidney-transplant recipients.
    Pol S; Marion O; Vallet-Pichard A; Meritet JF; Sauné K; Alric L; Kamar N
    Transpl Infect Dis; 2018 Jun; 20(3):e12864. PubMed ID: 29512231
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hepatitis B reactivation in patients with chronic hepatitis C undergoing anti-viral therapy with an interferon-free regimen.
    Londoño MC; Lens S; Mariño Z; Bonacci M; Ariza X; Broquetas T; Pla A; Bartres C; Adriani MV; Rodríguez-Tajes S; Costa J; Carrión JA; Pérez-Del-Pulgar S; Forns X
    Aliment Pharmacol Ther; 2017 Apr; 45(8):1156-1161. PubMed ID: 28206681
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Potential risk of HBV reactivation in patients with resolved HBV infection undergoing direct-acting antiviral treatment for HCV.
    Ogawa E; Furusyo N; Murata M; Toyoda K; Hayashi T; Ura K
    Liver Int; 2018 Jan; 38(1):76-83. PubMed ID: 28618152
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hepatitis B virus and hepatitis C virus treatment and management in patients receiving immune-modifying agents.
    Juan J; Feld JJ
    Curr Opin Rheumatol; 2014 Jul; 26(4):395-403. PubMed ID: 24841230
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Invasive Fungal Diseases in Children with Hematological Malignancies Treated with Therapies That Target Cell Surface Antigens: Monoclonal Antibodies, Immune Checkpoint Inhibitors and CAR T-Cell Therapies.
    Kyriakidis I; Vasileiou E; Rossig C; Roilides E; Groll AH; Tragiannidis A
    J Fungi (Basel); 2021 Mar; 7(3):. PubMed ID: 33807678
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hepatitis B surface antibody titres and hepatitis B reactivation with direct-acting antiviral therapy for hepatitis C.
    Poola S; Sanaka S; Sewell K; Tillmann HL
    J Viral Hepat; 2021 Feb; 28(2):373-382. PubMed ID: 33047433
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.